Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a...
Oramed Pharmaceuticals (NASDAQ: ORMP) was estab...
Magenta Therapeutics is a clinical-stage biotechnology company developing therapeu...
Magenta Therapeutics is a clinical-stage biotec...
Sierra Oncology is a clinical stage drug development company advancing targeted th...
Sierra Oncology is a clinical stage drug develo...
Aerie Pharmaceuticals is an ophthalmic pharmaceutical company focused on the disco...
Aerie Pharmaceuticals is an ophthalmic pharmace...
Syros is redefining the power of small molecules to control the expression of gene...
Syros is redefining the power of small molecule...
Ionis is a sustainably profitable, multi-product company with a pipeline of more t...
Ionis is a sustainably profitable, multi-produc...
ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdianÂŽ the wor...
ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufac...
Join the National Investor Network and get the latest information with your interests in mind.